Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,090 across all filing types
Latest filing 2017-08-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于向全资子公司上海厦维生物技术有限公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's capital increase investment into its wholly-owned subsidiary. It details the investment amount, the purpose, the approval by the board, and the impact on shareholding structure. It is not a full financial report but a specific update on financing activity related to capital injection. The document length is short (1659 characters) and it contains substantive information about the capital increase, not just a notice of report publication or certification. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2017-08-28 Chinese
第一届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Xiamen Aide Bio-Pharmaceutical Technology Co., Ltd. It reports the approval of the 2017 semi-annual report and its summary, a change in accounting policy, and the use of idle raised funds for cash management. The document states that the actual semi-annual report and related detailed announcements are published separately on the designated disclosure website. The document itself is short (1263 characters) and does not contain the full semi-annual report or detailed financial statements, but rather the Supervisory Board's approval and summary of decisions. This fits the pattern of a Regulatory Filing (RNS) as it is an official announcement related to regulatory compliance and disclosures but not the full financial report itself. It is not an Interim/Quarterly Report (IR) because it lacks substantive financial data and analysis, only referencing the report's approval. Therefore, the correct classification is Regulatory Filings (RNS).
2017-08-28 Chinese
关于使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Xiamen Aide Bio-Pharmaceutical Technology Co., Ltd. regarding the use of part of idle raised funds for cash management. It details the approval by the board and supervisory committee, the amount of funds involved, investment purpose, risk control measures, and opinions from independent directors, supervisory committee, and the sponsoring institution. The document references regulatory approvals and compliance with stock exchange rules. It does not contain financial statements or detailed financial performance data but is a disclosure about the company's use of idle raised funds. The document length is 3784 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the category of Capital/Financing Update (CAP), as it relates to the company's fundraising proceeds and their management.
2017-08-28 Chinese
关于2017年半年度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (327 characters) from a company about the disclosure of its 2017 half-year report. It states that the half-year report and summary have been disclosed on the official information disclosure website and advises investors to review it. There is no actual financial data or detailed report content included, only a notification of the report's availability. According to the 'MENU VS MEAL' rule, such a brief notice about the report's publication is classified as a Report Publication Announcement (RPA), not the report itself (which would be an Interim/Quarterly Report).
2017-08-28 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company listed on the Shenzhen Stock Exchange regarding an abnormal stock trading fluctuation on a specific date (August 23, 2017). It includes detailed explanations and risk disclosures related to the company's business, operations, and market environment. The document does not contain financial statements or quarterly/annual report data but focuses on explaining the stock price movement and confirming no undisclosed material information exists. This type of document is typically classified as a Regulatory Filing (RNS) because it is a regulatory disclosure about stock trading activity and company status, not a financial report or earnings release.
2017-08-23 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company listed on the Shenzhen Stock Exchange regarding abnormal stock price fluctuations over two trading days. It includes detailed explanations and risk disclosures related to the company's business, operations, and market environment. The document does not contain financial statements or quarterly/yearly financial results but focuses on stock trading behavior and risk factors. It is not an earnings release, annual report, or interim report. The content aligns with a regulatory announcement about stock price abnormality and risk disclosure, which is typical for a Regulatory Filing (RNS). The document length is about 7,924 characters, and it is a standalone announcement, not a report publication notice or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-08-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.